The 10th Chinese H. pylori and Digestive Diseases Forum was held in Beijing on August 21-23, 2015. Established in 2006, the forum has become one of the most important platforms for scientists, gastroenterologists and clinicians in relevant areas to exchange ideas and research results on H. pylori diagnosis and treatment in China. About 800 scientists and clinicians, including 130 nationally and internationally recognized experts in digestive disease area, participated in the meeting. Professor Barry Marshall, Nobel Prize laureate in Physiology or Medicine for his discovery of the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease, participated the meeting and give a lecture. Dr. Zhenkun Ma, founder and CEO of TenNor Therapeutics was invited to give a lecture on the development of a new generation of antibiotics for H. pylori eradication.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com